Labiotech.eu

News and Trends 21 Jul 2022

Poolbeg Pharma gets approval for severe influenza drug trial

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza. Clinical trial activities will formally commence on […]

July 21, 2022 - 4 minutesmins - By Jim Cornall

Interview 21 Jul 2022

Finding investment opportunities in a bleak biotech stock market

The situation remains difficult in public markets as biotech stocks struggle to recover from a 50% decline over the past year. However, the venture capital (VC) firm Sofinnova Partners is no stranger to downturns, and partner Joe Anderson explains how the industry is shifting in favor of life sciences investors. It’s a tough time to […]

July 21, 2022 - 7 minutesmins - By Jonathan Smith

coronavirus COVID 19 Europe biotech lungs

News and Trends 21 Jul 2022

Additional funding for trial to study drug targeting lung immunity in elderly patients

Lung immunity in the elderly will be the subject of a controlled clinical trial after receiving clearance to go ahead from Health Canada. Qu Biologics will receive additional funding to launch the trial for the restoration of innate immune function – the defense system humans are born with. Qu, a private clinical stage biopharmaceuticals company […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

Almirall launches new call to find innovative therapies for skin diseases

A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company

U.S. biopharma company ZyVersa Therapeutics, Inc., and Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, have entered into a definitive business combination agreement. The transaction is expected to provide ZyVersa with access to the public equity market, which the parties believe will escalate development of ZyVersa’s renal and inflammasome product candidate pipelines. Upon […]

July 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Jul 2022

Eiger receives European approval for progeria treatment

Eiger BioPharmaceuticals Inc., which focuses on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases, has received marketing authorization from the European Commission (EC) for Zokinvy (lonafarnib), a therapy for children and young adults with Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL). Collectively known as progeria, […]

July 21, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 21 Jul 2022

Vicebio exits stealth to work on next generation RSV vaccine

Vicebio Ltd, a biopharmaceutical company founded by Medicxi in 2019, has launched to accelerate the development of novel vaccines against life-threatening respiratory viral infections using its molecular clamp technology platform. The technology has been developed by Paul Young, Daniel Watterson, Keith Chappell and their groups at The University of Queensland (UQ), Brisbane, Australia. It was […]

July 21, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Jul 2022

IVI and Moderna sign MOU for vaccine R&D

The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and Moderna, a biotech company working on messenger RNA (mRNA) therapeutics and vaccines, have signed a Memorandum of Understanding (MOU) to partner on collaborative vaccine research and development. “IVI welcomes this […]

July 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jul 2022

BigHat Biosciences raises $75M to design safer, more effective antibodies

A company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today (July 20) announced it has raised $75 million in funding. BigHat Biosciences’ series B funding round was led by Section 32 with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital and others. […]

July 20, 2022 - 4 minutesmins - By Liza Laws

News and Trends 20 Jul 2022

Upstaza gets nod from Europe for AADC deficiency treatment

PTC Therapeutics, Inc. says Upstaza (eladocagene exuparvovec) has been given marketing authorization by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency, and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older. “Today’s approval from the European […]

July 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jul 2022

Iron protein can now be captured thanks to technology developed by NaviGo

An iron-storing protein can now be captured thanks to the successful development of a Precision Capturing affinity resin. Ferritin, an intracellular protein, is released into the bloodstream in small amounts where it acts as an iron carrier. Protein engineering company and developer of affinity ligands for custom chromatography solutions, NaviGo Proteins GmbH, announced today (July […]

July 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 20 Jul 2022

Plant-based nylon addressing urgent need for sustainable materials

Global brands need to take action by using sustainable materials with traceable and transparent supply chains, the CEO of a US biotech company says. Genomatica (Geno) alongside longtime collaborator Aquafil has just completed the first demonstration scale production runs for plant-based nylon-6. Christopher Schilling, Geno CEO says: “Now, more than ever, global brands are taking […]

July 20, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Poolbeg Pharma gets approval for severe influenza drug trial

Finding investment opportunities in a bleak biotech stock market

Additional funding for trial to study drug targeting lung immunity in elderly patients

Almirall launches new call to find innovative therapies for skin diseases

ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company

Eiger receives European approval for progeria treatment

Vicebio exits stealth to work on next generation RSV vaccine

IVI and Moderna sign MOU for vaccine R&D

BigHat Biosciences raises $75M to design safer, more effective antibodies

Upstaza gets nod from Europe for AADC deficiency treatment

Iron protein can now be captured thanks to technology developed by NaviGo

Plant-based nylon addressing urgent need for sustainable materials

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!